Table 8.

Clinical course according to dosage/interval

	Mean annual RTX dose (mg ± SD)				CD19+ B-cell counts at reinfusion/relapse when applicable (cells/µl ± SD)
	All patients	RRMS	SPMS	NMO/NMOSD	All patients	RRMS	SPMS	NMO
EDSS stable	1212 ± 793	1174 ± 787	1019 ± 770	1954 ± 838	70 ± 77	71 ± 72	91 ± 94	45 ± 81
EDSS worsened	1139 ± 702	1444 ± 1077	1071 ± 710	1822 ± 1114	67 ± 66	88 ± 86	57 ± 68	82 ± 81
p value	0.77	0.57	0.42	0.59	0.99	0.52	0.12	0.19
MRI stable	1257 ± 846	1260 ± 817	1009 ± 744	1784 ± 885	73 ± 79	84 ± 81	61 ± 67	56 ± 96
MRI progression	1168 ± 928	984 ± 891	983 ± 848	1842 ± 767	65 ± 77	46 ± 41	99 ± 108	57 ± 76
p value	0.39	0.14	0.51	0.67	0.48	0.08	0.49	0.67
Patients without clinical relapse	1284 ± 864	1148 ± 815	1022 ± 702	1727 ± 804	70 ± 79	80 ± 80	63 ± 67	47 ± 86
Patients with clinical relapse	1430 ± 947	1411 ± 924	1374 ± 1092	1986 ± 863	74 ± 80	62 ± 56	83 ± 94	75 ± 76
p value	0.46	0.33	0.54	0.59	0.76	0.46	0.96	0.27

Mean annual RTX dose = mean dose applied between the recorded variables (EDSS, MRI) during whole follow-up. MRI progression designates all new gadolinium-enhancing or new T2 lesions compared to previous MRI (cerebral and spinal) during whole follow-up

For patients with a relapsed CD19⁺ B-cell count indicates the first analysis/cell count after relapse and before re-dosing. For patients without a relapse, it is defined as highest available cell count before re-dosing

Data are expressed as mean ± SD where appropriate

EDSS Expanded Disability Status Scale, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disease, RTX rituximab, RRMS relapsing–remitting MS, SPMS secondary progressive MS